Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP

ELMWOOD PARK, N.J. — Glenmark Pharmaceuticals Inc., USA, the North American subsidiary of Mumbai-headquartered Glenmark Pharmaceuticals Limited, announced on Friday, August 21, 2026, the commercial launch of Calcium Gluconate Injection USP. The product is being introduced in $1,000\text{ mg}/10\text{ mL}$ ($100\text{ mg}/\text{mL}$) single-dose vials, $5,000\text{ mg}/50\text{ mL}$ ($100\text{ mg}/\text{mL}$) single-dose vials, and $10,000\text{ mg}/100\text{ mL}$ ($100\text{ mg}/\text{mL}$) pharmacy bulk packages across the United States market.

The product expansion targets an established U.S. institutional market valued at tens of millions of dollars. The launch represents a strategic push by the global pharmaceutical company to fortify its complex injectables pipeline and enhance supply stability for U.S. hospital networks.

Therapeutic Equivalence and Market Size

Glenmark's Calcium Gluconate Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Calcium Gluconate Injection ($1,000\text{ mg}/10\text{ mL}$, $5,000\text{ mg}/50\text{ mL}$, and $10,000\text{ mg}/100\text{ mL}$) of Fresenius Kabi USA, LLC.

According to IQVIA National Sales Perspectives data for retail and non-retail sectors during the 12-month period ending June 2026, the market for Calcium Gluconate Injection USP achieved annual U.S. sales of approximately $69.9 million.

In a official regulatory filing with Indian stock exchanges, Glenmark Pharmaceuticals Limited confirmed that the launch covers both single-dose formats for individual administration and pharmacy bulk packages designed for institutional compounding and bulk hospital operations.

Expansion of U.S. Hospital Injectables Portfolio

The addition of Calcium Gluconate Injection USP reinforces Glenmark’s commercial footprint within hospital systems and acute-care facilities across North America. The product is indicated for specific clinical uses as outlined in Glenmark's FDA-approved labeling.

"The launch of Calcium Gluconate Injection USP marks another important step in strengthening Glenmark's U.S. injectables business and expanding our hospital portfolio," said Marc Kikuchi, President & Business Head, North America. "It reflects the disciplined execution of our strategy to build a differentiated and sustainable injectables business—one that addresses institutional needs, supports greater supply resilience and deepens Glenmark's relevance across the U.S. healthcare system."

Parent company Glenmark Pharmaceuticals Ltd, which operates 11 manufacturing plants across four continents and six global research facilities, currently ranks among the top 100 biopharmaceutical companies globally by pharmaceutical sales.

Official Sources Section

According to regulatory filings submitted to BSE Limited (Scrip Code: 532296) and the National Stock Exchange of India Ltd (Symbol: GLENMARK) on August 21, 2026, Glenmark Pharmaceuticals Limited issued official announcement reference No. 52/26-27 under the signature of Rashmi Khandelwal, Company Secretary & Compliance Officer. Official product details and executive statements were formally distributed via the company’s corporate communications desk in Elmwood Park, New Jersey.

Executive Statements

According to Marc Kikuchi, President & Business Head, North America, at Glenmark Pharmaceuticals Inc., USA:

"The launch of Calcium Gluconate Injection USP marks another important step in strengthening Glenmark's U.S. injectables business and expanding our hospital portfolio. It reflects the disciplined execution of our strategy to build a differentiated and sustainable injectables business — one that addresses institutional needs, supports greater supply resilience and deepens Glenmark's relevance across the U.S. healthcare system."

Company officials further noted that the product will be marketed strictly for indications listed in Glenmark's approved label.

Why It Matters

The launch provides U.S. hospitals and healthcare providers with an alternative, therapeutically equivalent generic option for Calcium Gluconate Injection USP. Expanding the supplier base for essential injectable medications aids institutional buyers in mitigating drug shortages and maintaining supply continuity. For investors, entering a $69.9 million market segment further establishes Glenmark's steady growth in its North American hospital injectables division.

Key Facts at a Glance

• Product Launched: Calcium Gluconate Injection USP in $1,000\text{ mg}/10\text{ mL}$, $5,000\text{ mg}/50\text{ mL}$ single-dose vials, and $10,000\text{ mg}/100\text{ mL}$ pharmacy bulk packages.

• Reference Listed Drug (RLD): Fresenius Kabi USA, LLC's Calcium Gluconate Injection (NDA 208418).

• U.S. Market Value: Approximately $69.9 million for the 12 months ending June 2026 (IQVIA®).

• Target Audience: U.S. hospital networks, institutional pharmacies, and acute care facilities.

• Regulatory Authority: Filed with BSE and NSE on August 21, 2026.

Frequently Asked Questions

What product did Glenmark's U.S. unit launch on August 21, 2026?

Glenmark Pharmaceuticals Inc., USA launched Calcium Gluconate Injection USP in single-dose vials ($1,000\text{ mg}/10\text{ mL}$ and $5,000\text{ mg}/50\text{ mL}$) and pharmacy bulk packages ($10,000\text{ mg}/100\text{ mL}$).

What is the reference listed drug (RLD) for Glenmark's product?

Glenmark's generic equivalent is bioequivalent and therapeutically equivalent to Fresenius Kabi USA, LLC's Calcium Gluconate Injection.

How large is the U.S. market for Calcium Gluconate Injection USP?

According to IQVIA® sales data for the 12-month period ending June 2026, annual U.S. market sales were approximately $69.9 million.

Where will Glenmark's Calcium Gluconate Injection USP be sold?

The product will be distributed across institutional healthcare channels, hospitals, and medical facilities in the United States.

Source: Official regulatory announcements and press releases issued by Glenmark Pharmaceuticals Limited, BSE Limited, and the National Stock Exchange of India Ltd.